trastuzumab,lapatinib
novartis,roche
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'altto', 'breast']
#esmo22: brilliant on the identification of biologically-driven her2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the altto trial: her2+ bc is heterogeneous, with outcomes in luminal and immune-enriched 
MD, Medical Oncologist????•Research Fellow at @JulesBordet Institute in Brussels???? Great interest in #BreastCancer and #ImmunoOncology